Specify Company / Ticker to Get the Summary
Dividend History CMMB
Dividend Analytics CMMB
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Chemomab Therapeutics Ltd DRC
CMMBChemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. Address: Building 7, Tel Aviv, Israel, 6158002
Analytics
WallStreet Target Price
8.50 USDP/E Ratio
–Dividend Yield
–Financials CMMB
Results | 2019 | Dynamics |